Undesirable severe hepatic effects under tolcapone occuring 17 months after the onset of treatment;Effets indésirables hépatiques graves sous tolcapone survenus 17 mois après le début du traitement

Revue Neurologique

Volumn 161, Issue 11, 2005, Pages 1113-1115

  Korri, H ^a,b   Awada, A ^b  

^a Hôpital Bahman   (Lebanon)

^b SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; ENTACAPONE; PERGOLIDE; PERGOLIDE MESILATE; TOLCAPONE;

ADULT; AGED; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; FEMALE; HUMAN; LETTER; LIVER TOXICITY; PARKINSON DISEASE;

EID: 29444447637     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(05)85180-x     Document Type: Letter

References (6)

1. ASSAL F, SPAHR L, HADENGUE A et al. (1998). Tolcapone and fulminant hepatitis. Lancet, 352: 958.
2. BLUM MW, SIEGEL AM, MEIER R, HESS K. (2001). Neuroleptic malignant-like syndrome and acute hepatitis during tolcapone and clozapine medication. Eur Neurol, 46: 158-160.
3. FISHER A, CROFT-BAKER J, DAVIS M, PURCELL P, MCLEAN AJ. (2002). Entacapone-induced hepatotoxicity and hepatic dysfunction. Mov Disord, 6: 1362-1365.
4. NISSINEN E, KAHEINEN P, PENTILLA KE et al. (1997). Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease does not impair mitochondrial energy production. Eur J Pharmacol, 340: 287-294.
5. OLANOW W ET THE TASMAR ADVISORY PANEL. (2002). Tolcapone and hepatotoxic effects. Arch Neurol, 57: 263-267.
6. RAIPUT AH, MARTIN W, SAINT-HILAIRE MH et al. (1997). Tolcapone improves motor function in Parkinsonian patients with the "wearing off" phenomenon: a double blind, placebo-controlled, multicenter trial. Neurology, 49: 1066-1071.